Arbutus Biopharma Corp. (ABUS)

9.50
NASDAQ : Health Technology
Prev Close 9.95
Day Low/High 9.45 / 9.96
52 Wk Low/High 4.30 / 12.60
Avg Volume 514.50K
Exchange NASDAQ
Shares Outstanding 55.40M
Market Cap 551.27M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting ABUS Put And Call Options For August 17th

Interesting ABUS Put And Call Options For August 17th

Investors in Arbutus Biopharma Corp saw new options become available this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABUS options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Arbutus Announces Topline Results For ARB-1467 Phase II Cohort 4

Arbutus Announces Topline Results For ARB-1467 Phase II Cohort 4

Detailed Data to be Presented at AASLD in October

ABUS Crosses Above Average Analyst Target

ABUS Crosses Above Average Analyst Target

In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $6.62, changing hands for $6.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Arbutus To Host Live Webinar On Developments Of LNP Delivery For MRNA-based Therapeutics

Arbutus To Host Live Webinar On Developments Of LNP Delivery For MRNA-based Therapeutics

An Examination of the Rapidly Emerging field of mRNA Therapeutics in a Live Webinar hosted by the Nucleic Acid Drug Delivery Leader Arbutus Biopharma

TheStreet Quant Rating: E+ (Sell)